A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Plain-language summary

This study evaluates the effectiveness and safety of a gene therapy called LentiGlobin BB305 in patients with transfusion-dependent β-thalassemia who do not carry the β0/β0 genotype. It enrolled patients aged 50 and under who were eligible for stem cell transplant and did not have two β0 mutations in the HBB gene. It was conducted in Phase 3 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 3

Status

Completed

Sponsor

Genetix Biotherapeutics Inc.

Intervention

LentiGlobin BB305 Drug Product

Start date

8/8/2016

Estimated completion

3/31/2022

Countries

United States, France, Germany, Italy, Thailand, United Kingdom

Related genes

Locations

• Oakland, United States
• Chicago, United States
• Philadelphia, United States
• Marseille, France
• Hanover, Germany
• Rome, Italy
• Bangkok, Thailand
• London, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Participants \<= 50 years of age at the time of consent or assent (as applicable), and able to provide written consent (adults, or legal guardians, as applicable) or assent (adolescents or children). Provided that the Data Monitoring Committee (DMC) has approved enrolling participants younger than 5 years of age, participants younger than 5 years of age may be enrolled if they weigh a minimum of 6 kilograms (kg) and are reasonably anticipated to be able to provide at least the minimum number of cells required to initiate the manufacturing process.
* Diagnosis of TDT with a history of at least 100 milliliter per kilogram per year (mL/kg/year) of pRBCs in the 2 years preceding enrollment (all participants), or be managed under standard thalassemia guidelines with \>= 8 transfusions of pRBCs per year in the 2 years preceding enrollment (participants \>= 12 years).
* Clinically stable and eligible to undergo (HSCT).
* Treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.

Exclusion Criteria:

* Presence of a mutation characterized as β0 mutation at both alleles of the β-globin gene HBB.
* Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV).
* A white blood cell (WBC) count less than (\<) 3×10\^9/Liter (L), and/or platelet count \< 100×10\^9/L not related to hypersplenism.
* Uncorrected bleeding disorder.
* Any prior or current malignancy.
* Immediate family member with a known Familial Cancer Syndrome.
* Prior HSCT.
* Advanced liver disease.
* A cardiac T2\* \< 10 ms by MRI.
* Any other evidence of severe iron overload that, in the Investigator's opinion, warrants exclusion.
* Participation in another clinical study with an investigational drug within 30 days of Screening.
* Any other condition that would render the participant ineligible for HSCT, as determined by the attending transplant physician or investigator.
* Prior receipt of gene therapy.
* Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile participant.
* A known and available Human leukocyte antigen (HLA) matched family donor.
* Any contraindications to the use of granulocyte colony stimulating factor (G-CSF) and plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients.